News | Stent Grafts | February 14, 2019

Aortic Stent Graft Global Market to Reach $5.4 Billion by 2028

Abdominal aortic stent grafts will remain largest segment due to greater prevalence of abdominal aortic aneurysms

Aortic Stent Graft Global Market to Reach $5.4 Billion by 2028

February 14, 2019 — Abdominal aortic stent grafts will remain the largest segment in the global aortic stent graft market at least through 2028 due to the high prevalence of abdominal aortic aneurysms (AAA) relative to thoracic abdominal aneurysms (TAA), according to a new report from GlobalData. The abdominal segment will reach an estimated $2.8 billion global value by 2028, while the overall global aortic stent graft market is expected to reach $4.5 billion in the same period. This represents a compound annual growth rate of 5.4 percent between 2018 and 2028.

The company’s latest report, ‘Aortic Stent Grafts – Cardiovascular Market Analysis and Forecast Model’ reveals that Asia Pacific will be one of the fastest growing regions at a CAGR of 6.7 percent during the forecast period, with North America and Europe following closely behind at 4.9 percent and 4.6 percent, respectively.

David Brown, medical devices analyst at GlobalData commented, “Advances in stent graft design, such as with fenestrated and branched endografts, continue to expand the eligible patient pool for endovascular repair by addressing increasingly complex aneurysm anatomies.”

Although endovascular repair of aneurysms is a commonly used procedure and is increasingly employed over open repair procedures for the majority of aneurysms, barriers to market growth include the high cost of aortic stent graft devices and the relative lack of long-term outcome benefits versus open aortic repair.

For more information:

Related Content

Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Overlay Init